Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo — taking two 0.25mg Wegovy shots to make up 0.5mg is not safe and is not how the medicine works. The 0.25mg starting dose is a fixed tolerability step, not a building block you can stack. Each pen delivers one calibrated injection; doubling up risks a sudden spike in side effects without any proven benefit to weight loss. Wegovy is a prescription-only medicine and every dose decision belongs with your prescriber, not a workaround you apply at home.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It's an understandable thought. You've started Wegovy, the 0.25mg pen arrives (in a discreet box, tracked to your door) and after a few weeks you notice the scale barely moving. Surely two pens would do what one isn't?
The problem is that 0.25mg isn't a therapeutic dose in the usual sense. It exists entirely to let your digestive system adapt to semaglutide before the real treatment doses begin. NHS guidance on semaglutide is clear that nausea, vomiting and diarrhoea are the most common early side effects, and they are dose-dependent. Taking a second 0.25mg injection doesn't bypass the titration ladder; it simply doubles your exposure to those side effects before your body is ready.
Weight loss at this stage is genuinely not the goal. The prescribing schedule is built so that by the time you reach the maintenance dose your system tolerates it well. Skipping that process, even by half a step, works against you.
Two 0.25mg shots in quick succession mean your body receives a sudden 0.5mg load it hasn't been prepared for. Semaglutide slows gastric emptying, and that effect scales with dose. The result of doubling up can include prolonged nausea, uncontrolled vomiting, and the dehydration and kidney strain that severe vomiting brings.
There is also a practical medicine-safety point. Taking two Wegovy shots at once is not a licensed or studied approach: there is no clinical trial data on that pattern, and your prescriber cannot meaningfully oversee something they haven't approved. If anything goes wrong, you are outside the bounds of your prescription.
Beyond the immediate side effects, injecting into the same site or in close proximity raises the risk of injection-site reactions: redness, lumps or discomfort that can persist. Rotating sites matters even when following the proper schedule; doing two shots in a session makes that harder.
People sometimes feel that the starter dose isn't working because appetite suppression is subtle at 0.25mg. That's by design. The dose that changes appetite meaningfully comes later in the ladder. If you're at 0.25mg and feeling no effect, that's not a sign you need more right now, it's a sign the medicine is doing exactly what it should at this stage.
The thing to do if you feel stuck is to reach out to your prescriber. They can review your progress, check your adherence to the injection schedule, and tell you when the evidence supports moving up. At nume, every repeat order goes through a fresh clinical review by a GPhC-registered prescriber (not an automated process) before anything is dispensed. If your prescriber decides the next dose step is appropriate, that's how the increase happens: through a reviewed, documented decision, not by you combining pens yourself.
It's also worth being honest about timing. Taking your Wegovy shot early is a separate question many people ask alongside this one, and the answer there is similarly rooted in keeping to the schedule your prescriber has set.
If you're wondering whether you even qualify for a higher dose, the licensed criteria are worth knowing. Wegovy is approved in the UK for adults with a BMI of 30 or above, or 27 and above where at least one weight-related condition is present, conditions such as high blood pressure, raised cholesterol or type 2 diabetes. You can read more about the specific BMI criteria for Wegovy if you're unsure where you sit.
Eligibility alone doesn't determine which dose you should be on or when you move up. Your prescriber weighs your tolerance, your progress and your full health picture at each review. That's a clinical judgement, and it's the only safe basis for a dose decision. If you're thinking about starting Wegovy or switching provider, whether Wegovy is right for you is a good place to start, and a free consultation with our prescribers is the proper next step. For context on what the private cost of treatment looks like, our Wegovy price comparison page covers what to expect and what any quoted figure should include.
The short version: two shots of 0.25mg is not a shortcut. It's a risk, and a prescription-medicine question that belongs with a prescriber. Check your eligibility with our clinical team if you want a proper review of where you are in treatment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.